1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 4 and over
Sponsor: NCI
Protocol IDs: RPCI-I-72806, I 72806, NCT00536601
|
|
2.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2006-0374, NCT00539500
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 30 and under at diagnosis
Sponsor: NCI
Protocol IDs: COG-ANBL0032, ANBL0032, COG-P9842, NCT00026312
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 8 and under
Sponsor: NCI
Protocol IDs: COG-ANBL00P3, ANBL00P3, NCT00033293
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 12 and under
Sponsor: NCI
Protocol IDs: COG-ANBL0531, ANBL0531, NCT00499616
|
|
6.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 30 and under
Sponsor: NCI
Protocol IDs: COG-ANBL0532, ANBL0532, NCT00567567
|
|
7.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 1 to 18
Sponsor: NCI
Protocol IDs: COG-ACCL0431, ACCL0431, NCT00716976
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: FHCRC-1803.00, 5606, NCT00068718
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 75
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: ECP RIT, NCT00179790
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 20406, NCT00674427
|
|
12.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 21
Sponsor: Other
Protocol IDs: 22053, NCT00703222
|
|
13.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 months to 21 years
Sponsor: NCI
Protocol IDs: COG-ADVL0812, ADVL0812, NCT00739427
|
|
14.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CHNMC-07053, 07053, CA180 121, NCT00788125
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: Other
Protocol IDs: CHNY-06-533, IRB AAAC3457, NCT00801931
|
|
16.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 and over
Sponsor: Other
Protocol IDs: 6895, 2323.00, NCT00867139
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: MSKCC-03077, NCT00072358
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: PSCI-2003-232, NCT00084695
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 1
Sponsor: Other
Protocol IDs: MSKCC-04148, NCT00107289
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 29
Sponsor: NCI
Protocol IDs: NANT-2001-02, NCT00253435
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 years and under
Sponsor: Other
Protocol IDs: IRB# 0405652, NCT00202930
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: DFCI-04343, 04-343, NCT00357500
|
|
23.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 22
Sponsor: NCI
Protocol IDs: COG-ANBL0621, ANBL0621, NCI-07-C-0074, NCI-P6554, NCT00436852
|
|
24.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: MSKCC-05122, NCT00445965
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: NCI
Protocol IDs: COG-ADVL0525, ADVL0525, NCT00459147
|
